NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis study tests whether MB12, a proposed copy of the cancer drug Keytruda, works as well as the original when combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer. About 726 adults with stage IV disease who haven't had prior treatment will …
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New combo therapy targets hard-to-treat lung cancer
Disease control Recruiting nowThis study tests whether combining two drugs, BL-M07D1 and pembrolizumab, can shrink tumors in people with advanced HER2-positive non-small cell lung cancer. About 80 adults with cancer that has spread or cannot be removed by surgery will receive the treatment. The goal is to see…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
New hope for HER2-mutant lung cancer: targeted drug takes on standard chemo
Disease control Recruiting nowThis study compares a new drug, BL-M07D1, to standard chemotherapy for people with advanced or spreading non-squamous non-small cell lung cancer that has a specific HER2 gene mutation. About 440 adults will be randomly assigned to receive either the new drug or standard treatment…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
New drug rilvegostomig takes on pembrolizumab in advanced lung cancer showdown
Disease control Recruiting nowThis study compares two immunotherapy drugs—rilvegostomig and pembrolizumab—each given with standard chemotherapy as a first treatment for people with advanced non-squamous non-small cell lung cancer that has spread and shows a protein called PD-L1. About 878 participants will be…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo aims to stall lung cancer in patients with EGFR mutation
Disease control Recruiting nowThis study tests whether adding an experimental drug (telisotuzumab adizutecan) to a standard targeted therapy (osimertinib) works better than standard care for advanced non-small cell lung cancer with an EGFR mutation. About 854 adults will receive different doses of the combina…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Brazilian lung cancer study digs into Real-World treatment patterns
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 adults in Brazil with advanced non-squamous non-small cell lung cancer. It aims to describe what treatments patients receive after platinum chemotherapy stops working, and how they fare. No new treatments are given—researchers simpl…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC